Valiant Organics Ltd
Valiant Organics Ltd Q4 FY24 Results & Presentation Highlights: Revenue, Margins & Order Book
Q4 FY24 investor presentation: what the company reported on revenue, margins and projects.
Based on Valiant Organics Ltd's Q4 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Revenue from Operations for Q4 FY24 (consolidated): INR 7,231 million, down from INR 10,518 million in FY23, a decline of approximately 31.2% year-on-year. EBITDA for Q4 FY24: INR 396 Mn (Standalone), INR 382 Mn (Consolidated); standalone EBITDA margin 5.85%, consolidated 5.28%. - Year-on-year EBITDA decline: Standalone EBITDA down from INR 1,299 Mn in FY23 to 396 Mn in FY24; margin dropped from 14.25% to 5.85%.
From Valiant Organics Ltd's Q4 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q4 FY24 (consolidated): INR 7,231 million, down from INR 10,518 million in FY23, a decline of approximately 31.2% year-on-year.
- Standalone Revenue from Operations for FY24: INR 6,772 million, down from INR 9,116 million in FY23.
- EBITDA for Q4 FY24 (consolidated): INR 382 million, significantly down from INR 1,643 million in FY23.
- EBITDA for standalone FY24: INR 396 million, down from INR 1,299 million in FY23.
- No explicit quarterly volume or sales unit figures provided in the presentation.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Valiant Organics Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ortho Amino Phenol (OAP) project:
- Status: Expected to commence soon; trial run successful but further improvement needed.
- Purpose: Currently entirely imported in India; part of production to be used for forward integration of an existing product.
- Chlorophenol capacity expansion:
- Environmental approval obtained to increase capacity to 21,600 MTPA (page 7).
- PAP factory:
- Phase 1 completed and production ramped up to over 400 MT per month; multipurpose pharma intermediates plant commenced development (page 7).
- Investment figures:
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Valiant Organics Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Valiant Organics Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹218 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Valiant Organics Ltd's management said in earlier quarters
- Q2 FY25 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
Others in Chemicals & Petrochemicals this season
- Gujarat Alkalies & Chemicals Ltd (Q4 FY24)
951.17 Crores (Page 8) . Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q4 FY24 investor presentation — and how it ranks against se
- Himadri Speciality Chemical Ltd (Q4 FY24)
1,176.95 Cr, up 14.39% YoY from Rs. Key investor presentation takeaways from Himadri Speciality Chemical Ltd's Q4 FY24 investor presentation — and how it ranks
- Chemcon Speciality Chemicals Ltd (Q4 FY24)
Q4 FY24 Revenue from Operations: Rs 59.6 Cr, down 24.6% YoY from Rs 79.1 Cr in Q4 FY23 (Page 8, 6) . Key investor presentation takeaways from Chemcon Speciality
- Excel Industries Ltd (Q4 FY24)
Q4 FY24 revenue: ₹233.5 Cr, a 3.3% increase quarter-on-quarter and a 29.5% increase year-on-year (Page 11, 9, 7, 5). Key investor presentation takeaways from Ex
Frequently Asked Questions
What were Valiant Organics Ltd Q4 FY24 results?
Revenue from Operations for Q4 FY24 (consolidated): INR 7,231 million, down from INR 10,518 million in FY23, a decline of approximately 31.2% year-on-year. EBITDA for Q4 FY24: INR 396 Mn (Standalone), INR 382 Mn (Consolidated); standalone EBITDA margin 5.85%, consolidated 5.28%. - Year-on-year EBITDA decline: Standalone EBITDA down from INR 1,299 Mn in FY23 to 396 Mn in FY24; margin dropped from 14.25% to 5.85%.
What is Valiant Organics Ltd share price analysis?
Valiant Organics Ltd currently shows a neutral. The stock trades at a P/E of 23.7 with a market cap of ₹1,196 Cr. Investors should review the full earnings analysis for detailed insights.
Is Valiant Organics Ltd planning capital expenditure?
Ortho Amino Phenol (OAP) project: - Status: Expected to commence soon; trial run successful but further improvement needed.
Keep Valiant Organics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.